Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

GenMark Diagnostics Inc (GNMK) USD0.0001

Sell:$23.98 Buy:$23.99 Change: $0.005 (0.02%)
NASDAQ:0.26%
Prices delayed by at least 15 minutes | Switch to live prices |
Takeover

GenMark Diagnostics Inc USD0.0001

Type:
Takeover
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 1 Apr 2021)

What is happening?

 

As you may be aware the Boards of GenMark Diagnostics Inc and Geronimo Acquisition Corp, a wholly owned subsidiary company of Roche Holding AG, recently announced the terms of a Takeover, in the way of a Tender Offer.  The Offer price is USD24.05 for each GenMark Diagnostics Inc Share held.

 

What are my options?

 

Option 1 – Do nothing. You are not required to take any action at this time.

 

Option 2 – Accept the Offer. You can give an instruction to accept the Takeover Offer of USD24.05 for each GenMark Diagnostics Inc Share held. Following receipt of your instruction your Shares would be submitted in acceptance of the Offer.

 

The Hargreaves Lansdown client deadline is noon on Thursday 15 April 2021.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown Clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
Sell:$23.98
Buy:$23.99
Change: $0.005 (0.02%)
Prices delayed by at least 15 minutes | Switch to live prices |
Takeover

GenMark Diagnostics Inc USD0.0001

Type:
Takeover
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 1 Apr 2021)

What is happening?

 

As you may be aware the Boards of GenMark Diagnostics Inc and Geronimo Acquisition Corp, a wholly owned subsidiary company of Roche Holding AG, recently announced the terms of a Takeover, in the way of a Tender Offer.  The Offer price is USD24.05 for each GenMark Diagnostics Inc Share held.

 

What are my options?

 

Option 1 – Do nothing. You are not required to take any action at this time.

 

Option 2 – Accept the Offer. You can give an instruction to accept the Takeover Offer of USD24.05 for each GenMark Diagnostics Inc Share held. Following receipt of your instruction your Shares would be submitted in acceptance of the Offer.

 

The Hargreaves Lansdown client deadline is noon on Thursday 15 April 2021.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown Clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
Sell:$23.98
Buy:$23.99
Change: $0.005 (0.02%)
Prices delayed by at least 15 minutes | Switch to live prices |
Takeover

GenMark Diagnostics Inc USD0.0001

Type:
Takeover
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 1 Apr 2021)

What is happening?

 

As you may be aware the Boards of GenMark Diagnostics Inc and Geronimo Acquisition Corp, a wholly owned subsidiary company of Roche Holding AG, recently announced the terms of a Takeover, in the way of a Tender Offer.  The Offer price is USD24.05 for each GenMark Diagnostics Inc Share held.

 

What are my options?

 

Option 1 – Do nothing. You are not required to take any action at this time.

 

Option 2 – Accept the Offer. You can give an instruction to accept the Takeover Offer of USD24.05 for each GenMark Diagnostics Inc Share held. Following receipt of your instruction your Shares would be submitted in acceptance of the Offer.

 

The Hargreaves Lansdown client deadline is noon on Thursday 15 April 2021.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown Clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Contact details

Address:
5964 La Place Ct
CARLSBAD
92008-8829
United States
Telephone:
+1 (760) 4484300
Website:
https://www.genmarkdx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GNMK
ISIN:
US3723091043
Market cap:
$1.76 billion
Shares in issue:
73.60 million
Sector:
Health Care Equipment
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Kevin O'Boyle
    Independent Chairman of the Board
  • Scott Mendel
    President, Chief Executive Officer, Director
  • Johnny Ek
    Chief Financial Officer
  • Eric Stier
    Senior Vice President, General Counsel, Secretary
  • Michael Harkins
    Senior Vice President - Sales
  • Michael Gleeson
    Senior Vice President, Corporate Accounts
  • Tyler Jensen
    Senior Vice President - Engineering and Product Technical Support
  • Scott O'Brien
    Senior Vice President - Global Product Marketing and International Sales
  • Hollis Winkler
    Vice President - Human Resources

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.